[HTML][HTML] Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients
S Amit, G Regev-Yochay, A Afek, Y Kreiss, E Leshem - The Lancet, 2021 - thelancet.com
S Amit, G Regev-Yochay, A Afek, Y Kreiss, E Leshem
The Lancet, 2021•thelancet.comThis campaign coincided with a third wave of COVID-19, peaking at 10 116 daily new cases
by mid-January, 2021. The Sheba Medical Centre, Israel's largest hospital with 9647 HCWs,
began staff vaccination on Dec 19, 2020. All HCWs, excluding those with previous SARS-
CoV-2 infection, were eligible for vaccination. Clinical trial data of BNT162b2 vaccine
estimated an early vaccine efficacy in preventing COVID-19 of 52· 4% before dose two, and
90.5% on days 2–7 after dose two.
by mid-January, 2021. The Sheba Medical Centre, Israel's largest hospital with 9647 HCWs,
began staff vaccination on Dec 19, 2020. All HCWs, excluding those with previous SARS-
CoV-2 infection, were eligible for vaccination. Clinical trial data of BNT162b2 vaccine
estimated an early vaccine efficacy in preventing COVID-19 of 52· 4% before dose two, and
90.5% on days 2–7 after dose two.
This campaign coincided with a third wave of COVID-19, peaking at 10 116 daily new cases by mid-January, 2021. The Sheba Medical Centre, Israel's largest hospital with 9647 HCWs, began staff vaccination on Dec 19, 2020. All HCWs, excluding those with previous SARS-CoV-2 infection, were eligible for vaccination. Clinical trial data of BNT162b2 vaccine estimated an early vaccine efficacy in preventing COVID-19 of 52· 4% before dose two, and 90.5% on days 2–7 after dose two.
thelancet.com
以上显示的是最相近的搜索结果。 查看全部搜索结果